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Simona Lavinskiene*, Kestutis Malakauskas, Jolanta Jeroch, Deimante Hoppenot and Raimundas SakalauskasAbstract
Objective: We aimed to investigate peripheral blood eosinophil chemotaxis, generation of spontaneous reactive
oxygen species (ROS), and apoptosis in patients with allergic asthma after bronchial allergen challenge.
Material and methods: A total of 18 patients with allergic asthma (AA), 14 with allergic rhinitis (AR), and 10
healthy subjects (HS) underwent bronchial challenge with a specific allergen extract. Eosinophils from peripheral
blood were isolated 24 h before as well as 7 and 24 h after bronchial allergen challenge. Chemotaxis, spontaneous
ROS production in eosinophils, and apoptosis were analyzed by flow cytometry. Serum and induced sputum IL-5
levels were measured by ELISA; the cell count in sputum was analyzed by the May-Grünwald-Giemsa method.
Results: Before bronchial allergen challenge, peripheral blood eosinophil chemotaxis, spontaneous ROS production
was enhanced and eosinophil apoptosis was reduced in the patients with AA as compared with AR patients and
HS (P < 0.05). Meanwhile, eosinophil chemotaxis and ROS generation markedly increased in the patients with AA
7 h and 24 h after challenge compared with other groups and baseline values (P < 0.05). The percentage of
apoptotic eosinophils in the patients with AA decreased at 7 h as well as 24 h after challenge when compared with
other groups and the baseline values (P < 0.05). There was a significant correlation between the migrated peripheral
blood eosinophil count and the sputum eosinophil count (Rs = 0.89, P < 0.0001) and the sputum IL-5 level (Rs = 0.68,
P = 0.002) at 24 h after bronchial challenge only in the patients with AA. Furthermore, the percentage of peripheral
blood apoptotic eosinophils significantly correlated with eosinophil count in sputum (Rs = −0.53, P = 0.02), and ROS
production correlated with the serum IL-5 levels (Rs = 0.71, P = 0.01).
Conclusion: During allergen-induced late-phase airway inflammation, peripheral blood eosinophils demonstrated
further alterations of their functional activity manifested by enhanced spontaneous ROS production, increased
chemotaxis, and diminished apoptosis in patients with AA.
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Asthma is an inflammatory disorder of the airways in-
volving T‐cells, mast cells, and eosinophils [1]. The toxic
components of eosinophils are thought to be important
in inducing bronchial mucosal injury and dysfunction
[2]. Following airway allergen exposure, the development
of airway eosinophilia is associated with increased IL-5
expression in the sputum, elevated concentrations of* Correspondence: lavinskiene.simona@gmail.com
Department of Pulmonology and Immunology, Lithuanian University of
Health Sciences, Kaunas, Lithuanian
© 2015 Lavinskiene et al.; licensee BioMed Ce
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.IL-5 in luminal fluid and serum, and a heightened cap-
acity of airway cells for ex vivo generation of IL-5 [3-5].
IL-5 plays a key role in eosinophil proliferation, differ-
entiation, maturation, migration to tissue sites and sur-
vival, as well as prevention of eosinophil apoptosis [6,7].
Eosinophil chemotaxis to the lungs during allergic air-
way inflammation represents a major part of the inflam-
mation process [8]. Transmigration of the eosinophil
through the vascular endothelium is a multistep process;
rolling, tethering, firm adhesion, and transendothelial
migration are regulated by the coordinated interaction
between networks involving chemokine, cytokine andntral. This is an Open Access article distributed under the terms of the Creative
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allergen as well as endobronchial allergen challenge have
shown that blood and bronchoalveolar lavage eosinophils
from subjects with asthma have a greater responsiveness
to chemoattractants and enhanced chemotaxis [11,12].
During the process of allergic inflammation, eosinophils
release not only toxic granule proteins but also reactive
oxygen species (ROS), which are known to cause tissue
damage [13]. It has been demonstrated that allergic pa-
tients have upregulated oxidative metabolism in blood
eosinophils when compared with healthy subjects [14,15].
It leads to the observations that eosinophils isolated from
allergic patients might be already activated in peripheral
blood streams before they infiltrate the tissue.
In the absence of any inflammatory survival-prolonging
factors, eosinophils die by apoptosis in a few days, but in
inflamed airways, eosinophils survival is thought to be
prolonged due to the surrounding proinflammatory fac-
tors such as IL-5, IL-3, and granulocyte-macrophage
colony-stimulating factor [16,17]. There are some data
about impaired peripheral blood eosinophil apoptosis in
allergic patients [18], and this might contribute to greater
airway eosinophilia.
There is no doubt that eosinophils are important cells
which participate in allergic airway inflammation. Mean-
while, associations between eosinophil infiltration in the
airways and peripheral blood eosinophil chemotaxis,
ROS production, and apoptosis have not been com-
pletely elucidated yet. Therefore, the regulation of blood
eosinophil activity in asthmatic patients especially after
allergen challenge needs to be investigated.
We hypothesized that evaluating peripheral blood eo-
sinophils functional activity (chemotaxis, apoptosis, and
ROS production) during allergen-induced late-phase air-
way inflammation is important for understanding the
pathogenesis of eosinophilic inflammation in the airways.
Methods
Subjects
A total of 42 nonsmoking adults (13 men and 29 women)
were examined: 18 patients with intermittent or mild-to-
moderate persistent allergic asthma, defined according to
the GINA criteria [19], 14 patients with mild-to-moderate
persistent allergic rhinitis, defined according to the ARIA
criteria [20], and 10 healthy subjects who comprised the
control group. The patients were recruited from the De-
partment of Pulmonology and Immunology, Hospital of the
Lithuanian University of Health Sciences, Kaunas. The
study protocol was approved by the Regional Biomedical
Research Ethics Committee of the Lithuanian University of
Health Sciences (BE-2-23), and each participant gave his/
her informed written consent. The study was registered in
the U.S. National Institutes of Health trial registry Clinical-
Trials.gov with identifier NCT02214303.Patients with allergic asthma and rhinitis had a clinical
history of the disease for ≥1 year, current symptoms, and
positive results of skin prick test (≥3 mm) with the fol-
lowing allergens: Dermatophagoides pteronyssinus (D.
pteronyssinus), birch pollen, or mixture of 5 grasses. All
the patients were not using inhaled, nasal, or oral ste-
roids at least 1 month before visits; short-acting β2 ago-
nists, at least 12 h; long-acting β2 agonists, at least 48 h
prior the lung function test, and antihistamines and
antileukotrienes, 7 days before the skin prick test and
the lung function test. None of the patients had a history
of smoking. Baseline forced expiratory volume in one
second (FEV1) was more than 70% of the predicted value
in all patients. All the healthy subjects were nonsmokers,
without symptoms of asthma or rhinitis, with normal
findings of spirometry, and all showed negative results
of the skin prick test.Skin prick and lung function testing
All the patients were screened for allergy by the skin prick
test using standardized allergen extracts (Stallergenes S.A.,
France) for the following allergens: D. pteronyssinus, D.
farinae, cat and dog dander, mixture of pollen of 5 grasses,
birch pollen, mugwort, Alternaria, Aspergillus, and Cla-
dosporium. Histamine hydrochloride (10 mg/mL) was
used for a positive control. Skin testing was read 15 min
after application. The results of the skin prick test
were considered positive if the mean wheal diameter
was ≥ 3 mm [21].
Pulmonary function was tested using a pneumotacho-
metric spirometer “CustovitM” (Custo Med, Germany).
Baseline FEV1, forced vital capacity (FVC), and FEV1/
FVC ratio were recorded as the highest of three repro-
ducible measurements. The results were compared with
the predicted values matched for age, body height, and
sex according to the standard methodology [22].Measurement of airway responsiveness to methacholine
Airway responsiveness was assessed as changes in the
airway function after challenge with inhaled methacho-
line using a reservoir method [23]. Methacholine was
nebulized into a 10-L reservoir with a pressure nebulizer
(Pari Provocation I; Pari, Stanberg, Germany). Aerolized
methacholine was inhaled through a one-way valve at 5-
min intervals starting with 15-μg methacholine dose and
doubling it until a 20% decrease in FEV1 from the
baseline or the total cumulative dose of 3.87 mg was
achieved. The bronchoconstricting effect of each dose of
methacholine was expressed as a percentage of decrease
in FEV1 from the baseline value. The provocative dose
of methacholine causing a ≥ 20% fall in FEV1 (PD20) was
calculated from the log dose–response curve by linear
interpolation of two adjacent data points.
Lavinskiene et al. Journal of Inflammation  (2015) 12:25 Page 3 of 9Peripheral blood collection and isolation of eosinophils
Peripheral blood samples for eosinophil isolation were
collected into sterile vacutainers with ethylenediamine-
tetraacetic acid (EDTA). Polymorphonuclear leukocytes
(PMNs) were isolated by high density gradient centrifuga-
tion. The whole blood was layered on Ficoll-Paque PLUS
(GE Healthcare, Finland) and centrifuged at 1000 g for
30 min at room temperature. PMNs were separated by
hypotonic lysis of erythrocytes and eosinophils were sepa-
rated using a magnetic eosinophil isolation kit (Miltenyi
Biotek, USA). Isolated eosinophils were diluted in cell cul-
ture RPMI 1640 media (Biological Industries, Israel) at a
final concentration of 2 × 106/mL. The viability of eo-
sinophil was checked flow cytometrically using propi-
dium iodide (2 mg/mL) and it always was > 95 %.Sputum induction and processing
The subjects inhaled 10 mL of sterile hypertonic saline
solution (3%, 4%, or 5% NaCl, Ivex Pharmaceuticals,
USA) at room temperature from an ultrasonic nebulizer
(DeVilbiss Health Care, USA). The duration of each in-
halation was 7 min, and it was stopped after expector-
ation an adequate amount of sputum. In order to detect
a possible decrease in FEV1, spirometry was performed
after each inhalation. Sputum was poured into a Petri
dish and separated from saliva. A 4-fold volume of
freshly prepared 0.1% dithiothreitol (DTT; Sigma-Aldrich)
was added. The mixture was vortexed and placed on a
bench rocker for 15 min at room temperature. Next, an
equal volume of phosphate-buffered saline solution (PBS;
Sigma-Aldrich) was added to DTT. The cell pellet was
separated using a 40-μm cell stainer (Becton Dickinson,
USA). The mixture was centrifuged for 10 min at 4°C;
the supernatant was aspirated and stored at −70°C for
later analysis. The total cell counts, percentage of epi-
thelial cells, and cell viability were investigated using a
Neubauer hemocytometer (Heinz-Herenz, Germany)
under a microscope (B5 Professional, Motic, China)
by employing the Trypan blue exclusion method.
The cytospin samples of induced sputum were pre-
pared using a cytofuge instrument (Shandon Southern
Instruments, USA).Induced sputum cell analysis
The prepared sputum cytospins were stained by the
May-Grünwald-Giemsa method for differential cell counts.
Cell differentiation was determined by counting approxi-
mately 400 cells in random fields of view under a light
microscope, excluding squamous epithelial cells. The cells
were identified by standard morphological criteria, nuclear
morphology, and cytoplasmic granulation. Cell counts
were expressed as percentages of total cells and absolute
values (106/L).Peripheral blood eosinophil chemotaxis,
apoptosis and ROS production assay
Chemotaxis in vitro
Eosinophil chemotaxis in vitro was performed in a 10-
well cell transmigration chamber (Neuro Probe, USA).
The lower and upper wells of chamber were isolated by
a polyvinylpyrrolidone (PVP)-treated polycarbonate track-
etch membrane, containing 2 × 106 3 μm/mm2 pores
(Neuro Probe, USA). The lower wells were pre-filled
with isotonic Percoll (GE Healthcare, Finland) and
eotaxin, a chemotactic factor, at different concentrations
(10, 100, or 1000 ng/mL). RPMI 1640 was used as a
negative control. The upper wells were filled with eo-
sinophil culture suspension (1 × 103/mL) and incubated
for 2 h (37°C, 5% CO2).
After the incubation, the suspensions of upper and
lower wells were resuspended in tubes for flow cytome-
try. Nonmigrated eosinophils remained in the upper
wells. The migration rate was calculated from the total
number of eosinophils harvested from the lower well
and expressed as percentage of the total input of eosino-
phils into the upper well.
The number of migrated eosinophils was calculated by
flow cytometry using Liquid Counting Beads (BD Biosci-
ences, USA) according to the manufacturer’s recommen-
dations. The amount of migrated eosinophils was
expressed in percentages.
Apoptosis
Isolated eosinophils were resuspended in the annexin-
binding buffer (pH 7.4) containing 50 mM HEPES,
700 mM NaCl, 12.5 mM CaCl2 (Invitrogen, USA) and
incubated with fluorescein isothiocyanate-labeled (FITC)-
annexin V (Invitrogen, USA) and propidium iodide (PI)
for 15 min at room temperature in the dark. After the in-
cubation, apoptosis was analyzed by flow cytometry using
the CellQuest software (BD Biosciences, USA). Apoptotic
cells were quantified as the percentage of the total popula-
tion that was positive for FITC, but negative for PI. Nec-
rotic cells were positive for PI.
Analysis of ROS production
Spontaneous ROS production in peripheral blood eo-
sinophils was performed in sterile 96-well microplates
(Falcon, BD, USA). For the detection of generated ROS,
dihydrorhodamine-123 (DHR-123, 750 ng/mL final,
Invitrogen, USA), a nonfluorescent dye, was added.
DHR-123, interacting with intracellular ROS, is oxidized
to the green-fluorescent rhodamine-123.The plates were
filled with eosinophil cultures and incubated for 45 min
(37°C, 5% CO2). The relative amount of generated ROS
was measured flow cytometrically by determination of
mean green fluorescence intensity in the eosinophil
population.
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supernatant
The serum and sputum IL-5 levels were measured by an
enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s instructions (Abcam, USA). The
minimum detectable concentration was 5 pg/mL.
The peripheral blood cell analysis was performed on
an automated hematology analyzer (Sysmex XE-5000,
Japan).
Statistical analysis
Statistical analysis was performed by using the Statistical
Package for Social Sciences, version 17.0 for Windows
(SPSS 17.0). The normality assumption of data was veri-
fied with the Kolmogorov-Smirnov test. The data were
expressed as a median and a range. The results of
methacholine PD20 measurements are expressed as a
geometric mean. PD20 values were log-transformed for
analysis to fit a normal distribution.
Due to a skewed distribution of the variable, nonpara-
metric tests were applied. The Kruskal-Wallis test was
used to evaluate differences between the groups of
patients and the control group. Differences between 2
independent groups were determined by the Mann–
Whitney U test. Differences among 3 and more paired
samples were evaluated by the Friedman test. Differ-
ences between 2 dependent samples were evaluated by
the Wilcoxon test. The Spearmen rank test was used to
assess relationships between measurements. Statistical
significance was assumed at a P value of <0.05.
Results
Characteristics of studied subjects
A total of 42 nonsmoking adults (17 men and 25
women; mean age 31 ± 9 years) were examined: 18 pa-
tients with intermittent or mild-to-moderate persistent
allergic asthma, 14 patients with mild-to-moderate per-
sistent allergic rhinitis, and 10 healthy subjects who
comprised the control group. There were no significantTable 1 Demographic and clinical characteristics of study sub
Characteristics Patients wN = 18
Age (years), median (range) 31 (21–50)
Sex (male/female), n 10/8
Wheal diameter induced by allergen (mm), median (range) 6.2 (4–11)
Sensitization to D. pteronyssinus/birch/5 grass mixture allergen, n 13/3/2
PD20 (mg), geometric mean (range) 0.38 (0.25–
FEV1 (% of predicted), mean ± SD 98 ± 15
*N = 1 because methacholine challenge provoked bronchoconstriction only to one
PD20 - a provocative dose of methacholine causing a 20% decrease in FEV1;
FEV1 - forced expiratory volume in one second.age and gender differences comparing the groups. Twenty-
one patients were sensitized to D. pteronyssinus; 5 patients,
to birch pollen; and 6 patients, to a mixture of pollen of 5
grasses. The mean wheal diameter induced by an allergen
was similar in both groups of patients. The demographic
and clinical data of the study subjects are presented in
Table 1. There were no significant difference in the baseline
FEV1 (% of predicted) the comparing all groups. A provoca-
tive dose of methacholine causing a 20% decrease in FEV1
(PD20) was documented in 18 patients with allergic asthma
and 1 patient with allergic rhinitis.
Eosinophil composition of peripheral blood and induced
sputum
The eosinophil count in the peripheral blood 24 h before
bronchial allergen challenge was significantly higher in
the patients with allergic asthma compared with the
patients with allergic rhinitis and healthy subjects
(0.32 × 109/L [range, 0.09–0.65] vs. 0.16 × 109/L [0.04–
0.88] and 0.13 × 109/L [0.04–0.94], P <0.05). At
24 hours after bronchial challenge, the peripheral
blood eosinophil count was significantly increased in
the patients with allergic asthma compared with the
baseline values and the healthy subjects (Figure 1A).
The increased peripheral blood eosinophil count also
was recorded 24 h after bronchial challenge in the pa-
tients with allergic rhinitis compared with the baseline
values (0.22 × 109/L [range, 0.04–1.19] vs. 0.16 × 109/L
[range, 0.04–0.88], P < 0.05). Meanwhile, at the base-
line as well as 7 h and 24 h after bronchial challenge,
the total eosinophil count in the sputum was significantly
higher in the patients with allergic asthma than those
with allergic rhinitis and the healthy subjects (P < 0.05)
(Figure 1B). At the baseline as well as 7 h and 24 h after
bronchial challenge, the patients with allergic rhinitis
showed a significantly greater eosinophil count in the
sputum than the healthy subjects (P < 0.05). Bronchial
allergen challenge had no impact on eosinophil count in
healthy subjects.jects
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Figure 1 Eosinophil count of patients with allergic asthma, allergic rhinitis and healthy subjects. A Eosinophil counts in peripheral blood
24 h before as well as 7 h and 24 h after bronchial challenge. B Eosinophil counts in the induced sputum 24 h before as well as 7 h and 24 h
after bronchial challenge. Data are shown as median (range). AA indicates patients with allergic asthma (n = 18); AR, patients with allergic rhinitis
(n = 14); HS, healthy subjects (n = 10). *P < 0.05 compared with healthy subjects; #P < 0.05 compared with baseline values; †P < 0.05 compared
with patients with allergic rhinitis.
Figure 2 Peripheral blood eosinophil chemotaxis (stimulated
with 1000 ng/mL of eotaxin) in patients with allergic asthma,
patients with allergic rhinitis, and healthy subjects 24 h before
as well as 7 h and 24 h after bronchial challenge. Data are shown
as median (range). AA indicates patients with allergic asthma
(n = 18); AR, patients with allergic rhinitis (n = 14); HS, healthy
subjects (n = 10). *P < 0.05 compared with healthy subjects; #P < 0.05
compared with baseline values; †P < 0.05 compared with patients with
allergic rhinitis.
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Peripheral blood eosinophil chemotaxis in vitro
Eotaxin at different concentrations (10, 100, and
1000 ng/mL) had an impact on peripheral blood eosino-
phil chemotaxis in all the studied groups, but the highest
concentration had the greatest effect. At the baseline, per-
ipheral blood eosinophil chemotaxis after the stimulation
with 1000 ng/mL of eotaxin was higher in the patients
with allergic asthma compared with those with allergic
rhinitis and the healthy subjects (P < 0.05). At 7 h and
24 h after bronchial challenge, eosinophil chemotaxis was
significantly enhanced in the patients with allergic asthma
compared with the baseline values, and it was greater than
in the patients with allergic rhinitis and the healthy sub-
jects (Figure 2). Meanwhile, bronchial allergen challenge
had no significant effect on eosinophil chemotaxis in the
peripheral blood of healthy subjects.
ROS in peripheral blood eosinophils
Before bronchial allergen challenge, spontaneous ROS
production in peripheral blood eosinophils was signifi-
cantly greater in the patients with allergic asthma com-
pared than those with allergic rhinitis and the healthy
subjects (P < 0.05). At 7 h and 24 h after bronchial chal-
lenge, ROS generation was significantly greater in the pa-
tients with allergic asthma compared with other groups
and the baseline values (Figure 3). Bronchial allergen chal-
lenge had no impact on ROS production in eosinophils
isolated from the healthy subjects.
Apoptosis of peripheral blood eosinophils
Before bronchial allergen challenge, the patients with
allergic asthma had a significantly lower percentage of
apoptotic peripheral blood eosinophils than those withallergic rhinitis and the healthy subjects (P < 0.05) (Figure 4).
Furthermore, 7 h and 24 h after bronchial challenge, a sig-
nificantly lower percentage of apoptotic peripheral blood
eosinophils was recorded in the asthma patents’ group
when compared with other groups and the baseline values
(P < 0.05).
IL-5 Levels in induced sputum and serum
There was a significant increase in the induced sputum
IL-5 levels in the patients with allergic asthma and those
with allergic rhinitis compared with the healthy subjects
at 24 h before bronchial challenge (Figure 5A). At 7 h
Figure 3 Production of reactive oxygen species in peripheral
blood eosinophils of patients with allergic asthma, patients
with allergic rhinitis, and healthy subjects 24 h before as well
as 7 h and 24 h after bronchial challenge. Data are shown as
median (range). AA indicates patients with allergic asthma (n = 18);
AR, patients with allergic rhinitis (n = 14); HS, healthy subjects (n = 10);
MFI, mean fluorescence intensity. *P < 0.05 compared with healthy
subjects; #P < 0.05 compared with baseline values; †P < 0.05 compared
with patients with allergic rhinitis.
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IL-5 levels increased significantly in the patients with al-
lergic asthma and those with allergic rhinitis compared
with the healthy subjects. Moreover, the sputum IL-5
levels at 7 h and 24 h after bronchial challenge were sig-
nificantly higher in the patients with allergic asthma
than those with allergic rhinitis. The same tendency was
observed while analyzing serum IL-5 levels (Figure 5B).
However, in patients with allergic rhinitis, there was no
significant difference in the serum IL-5 levels comparingFigure 4 The percentage of apoptotic peripheral blood
eosinophils in patients with allergic asthma, patients with
allergic rhinitis, and healthy subjects 24 h before as well as
7 h and 24 h after bronchial challenge. Data are shown as median
(range). AA indicates patients with allergic asthma (n = 18); AR,
patients with allergic rhinitis (n = 14); HS, healthy subjects (n = 10).
*P < 0.05 compared with healthy subjects; #P < 0.05 compared with
baseline values; †P < 0.05 compared with patients with allergic rhinitis.the baseline values with those recorded 7 h after bronchial
challenge. Bronchial challenge had no impact on the IL-5
levels in the sputum and serum of healthy subjects.
Correlations
Significant correlations were found only in the patients
with allergic asthma at 24 h after bronchial allergen
challenge. The migrated peripheral blood eosinophil
count significantly correlated with the eosinophil count
in the sputum (Rs = 0.89, P < 0.0001; Figure 6A). Moreover,
there was a significant correlation between the percentage
of apoptotic peripheral blood eosinophils and eosinophil
count in sputum (Rs = −0.53, P =0.02; Figure 6B). The mi-
grated peripheral blood eosinophil count significantly cor-
related with sputum IL-5 levels (Rs = 0.68, P = 0.002;
Figure 6C), and ROS production in peripheral blood eo-
sinophils significantly correlated with the serum IL-5 levels
(Rs = 0.71, P = 0.01; Figure 6D).
Discussion
This study has demonstrated that peripheral blood eosino-
phil chemotaxis, spontaneous ROS production, and eosino-
phil apoptosis are altered in patients with allergic asthma
during allergen-induced late-phase airway inflammation.
The increased sputum eosinophil count and enhanced
levels of IL-5 significantly correlated with the impaired
functional activity of peripheral blood eosinophils.
It is known that eosinophils are recruited to sites of in-
flammation by released chemotactic agents. Eotaxin, a
CC chemokine, is one of the strongest stimulator of eo-
sinophil chemotaxis [24]. It also induces the release of
various mediators from eosinophils and is known to play
an integral role in the development of eosinophilic
inflammation [25]. Therefore, in order to investigate
chemotaxis in vitro, peripheral blood eosinophils were
stimulated with different concentrations (10, 100, and
1000 ng/mL) of eotaxin. Our results showed that before
bronchial allergen challenge, peripheral blood eosinophil
chemotaxis stimulated with the highest eotaxin concen-
tration was greatest in the patients with allergic asthma
as compared with other groups. These data suggest that
eosinophils in the peripheral blood of individuals with
allergic asthma are already primed and more sensitive to
a chemokine.
Experiments with in vivo injection of eotaxin into the
skin of mice and rhesus monkeys showed local accumula-
tion of eosinophils, and the kinetics of allergen-induced
production of eotaxin is paralleled by eosinophil accumu-
lation in a guinea-pig model of allergic airways [25,26].
We found that 7 h and 24 h after bronchial allergen
challenge, eosinophil chemotaxis was significantly greater
in the patients with allergic asthma than other groups and
also compared with the baseline values. This shows that
not only allergen challenge stimulates the functional
Figure 5 IL-5 levels of patients with allergic asthma, patients with allergic rhinitis, and healthy subjects. A IL-5 levels in the induced
sputum 24 h before as well as 7 h and 24 h after bronchial allergen challenge. B IL-5 levels in serum 24 h before as well as 7 h and 24 h after
bronchial allergen challenge. Data are shown as median (range). AA indicates patients with allergic asthma (n = 18); AR, patients with allergic
rhinitis (n = 14); HS, healthy subjects (n = 10). *P < 0.05 compared with healthy subjects; #P < 0.05 compared with baseline values; †P < 0.05
compared with patients with allergic rhinitis.
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the undeniable importance of this chemokine. More-
over, at 24 h after bronchial challenge, the increased eo-
sinophil count in the sputum significantly correlated
with the increased migrated eosinophil count in the per-
ipheral blood of asthmatic patients. That can reflect the
hallmark characteristic of allergic asthma by infiltration
of eosinophils to the airway.
The inflammatory cells recruited to the asthmatic air-
ways are exceptionally capable of producing ROS, result-
ing in abnormal physiologic function of DNA, proteins,
and lipids that clinically can augment bronchial hyperre-
sponsiveness and inflammation [27]. However due to the
possibility that eosinophils can be already activated in
periphery, we examined spontaneous ROS production in
peripheral blood eosinophils.
Our study showed that spontaneous ROS production
in peripheral blood eosinophils was significantly greater
in the patients with allergic asthma than those with al-
lergic rhinitis and the healthy subjects. Moreover, at 7 h
and 24 h after bronchial allergen challenge, ROS gener-
ation in peripheral blood eosinophils was significantly
greater in the patients with allergic asthma compared
with the baseline values and other groups.
The upregulation of ROS production by blood eosino-
phils in allergic patients has been previously documented
in several studies [14,28], and the results of these studies
as well as our date suggest that eosinophils from allergic
asthma patients may might be already activated in the per-
ipheral blood stream before they infiltrate the tissues and
the inhalation of aggravating compounds such as allergens
can promote stronger activation of these cells.
Moreover, it was demonstrated that a low concentra-
tion of IL-5 enhanced chemokine-primed ROS produc-
tion by eosinophils [14]. Consequently, we evaluated thelevels of serum IL-5 and looked for a relationship with
generated ROS in peripheral blood eosinophils. We
found elevated serum IL-5 levels, especially 24 h after
bronchial challenge, in the patients with allergic asthma
compared with the baseline values and other groups.
Moreover, a significant correlation was observed only
24 h after bronchial challenge and only in the patients
with allergic asthma. The increased serum IL-5 levels
correlated with the enhanced ROS production in periph-
eral blood eosinophils (P < 0.05). These findings suggest
that enhanced ROS generation can activate a number of
redox-sensitive signaling cascades, stimulate production-
interaction of proinflammatory cytokines, and promote
inflammation [29].
As it has been reported that IL-5 can enhance eosino-
phil migration by the upregulation of adhesion molecules
on eosinophils [30], we analyzed sputum IL-5 levels and
investigated the possible relationship to peripheral blood
eosinophil chemotaxis. Thus, we determined a significant
increase in sputum IL-5 levels in the patients with allergic
asthma, and it correlated with the migrated peripheral
blood eosinophil count in allergen-induced late-phase
airway inflammation in asthma patients.
The accumulation of eosinophils in the asthmatic lungs is
a complex process, which involves their maturation in and
release from the bone marrow, adhesion and transmigra-
tion through the post-capillary endothelium, and then their
chemotaxis to and activation/degranulation at inflamma-
tory foci [9,31]. In the circulation and tissues, eosinophils
are programmed to undergo apoptosis in the absence of
viability-enhancing stimuli [31]. A defect in apoptosis might
contribute to chronic tissue eosinophilia associated with
asthma. Therefore, we aimed at evaluating peripheral blood
eosinophil apoptosis during allergen-induced late-phase in-
flammation. Before bronchial challenge, the percentage of
Figure 6 Correlations between peripheral blood eosinophil activity and eosinophil count as well as IL-5 levels in the induced sputum
in the patients with allergic asthma 24 h after bronchial allergen challenge. A Correlation between migrated peripheral blood eosinophil
count and eosinophil count in sputum. B Correlation between percentage of apoptotic peripheral blood eosinophils and eosinophil count in
sputum. C Correlation between migrated peripheral blood eosinophil count and IL-5 level in sputum. D Correlation between ROS production in
peripheral blood eosinophils and serum IL-5 levels. MFI indicates mean fluorescence intensity.
Lavinskiene et al. Journal of Inflammation  (2015) 12:25 Page 8 of 9apoptotic peripheral blood eosinophils in the patients with
allergic asthma was significantly lower compared with the
patients with allergic rhinitis and the healthy subjects.
Apoptosis of peripheral blood eosinophils in the patients
with allergic asthma was more delayed 7 h and 24 h after
bronchial challenge compared with the baseline and other
groups. The same tendency was reported by Evans et al.,
who showed that in asthmatic patients demonstrating a late
response, the survival of peripheral blood eosinophils is
prolonged after the whole lung allergen challenge [32].
Moreover, Druilhe et al. and Vignola et al. demonstrated
that asthmatic patients had greater numbers of eosinophils
in the bronchial biopsy than healthy individuals [33,34]. All
the above-mentioned results and findings of our study
show that eosinophil survival through the inhibition of
apoptosis can increase airway eosinophilia.Finally, we evaluated relationships between eosinophil
counts in the sputum and eosinophil viability after bron-
chi al allergen challenge, which could represent a link
between eosinophilic influx to the airways possibly
caused by delayed peripheral blood eosinophil apoptosis
in allergen-induced late-phase airway inflammation.
Significant correlations were observed only 24 h after
bronchial challenge and only in the patients with allergic
asthma. The lower percentage of peripheral blood eosino-
phils was negatively correlated with the increased eosino-
phil count in the sputum. It might be that diminished
apoptotic potential represents a mechanism that promotes
resolution of eosinophilic inflammation in asthma.
In conclusion, this study has shown that allergic
asthma patients demonstrates enhanced spontaneous
ROS production, increased chemotaxis, and diminished
Lavinskiene et al. Journal of Inflammation  (2015) 12:25 Page 9 of 9apoptosis of peripheral blood eosinophils, and these al-
terations are more pronounced during allergen-induced
late-phase airway inflammation.
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